Source: Genomeweb

Indivumed GmbH: Indivumed, CellPhenomics Partner on Cancer Drug Target Research

The two German companies will share tumor data for AI-based in silico target discovery and in vitro validation.

Read full article »
Est. Annual Revenue
$5.0-25M
Est. Employees
100-250
Hartmut Juhl's photo - Founder & CEO of Indivumed GmbH

Founder & CEO

Hartmut Juhl

CEO Approval Rating

82/100

Read more